The prevalence of all common categories of movement disorders was 28·0% (95% CI 25·9–30·1). Proportions in men (27·6% [95% CI 24·5–30·7]) and women (28·3% [25·5–31·2]) were closely similar and sharply increased with age (from 18·5% [15·0–22·0] in 50–59-year olds to 51·3% [44·9–57·7] in 80–89-year olds). Almost half of all patients (90/214) had moderate-to-severe disease expression, but only 7·0% (15/214) received standard drug treatment.
Non pharmacological treatment include treatment of sleep apnea via a continuous positive airway pressure (CPAP) device has shown dramatic improvement in apnea and nearly complete resolution of RMD symptoms. Behavioral interventions may alleviate some RMD symptoms and movements. In such a therapy, sufferers are asked to perform RMD-like motions during the day in a slow and methodic manner.
Movement disorder was suppressed by test stimulation of the thalamic ventralis intermedius (VIM) nucleus at high frequency (130 Hz) during stereotaxy in nonanesthetized patients suffering from Parkinson's disease or essential tremor. Ventralis intermedius stimulation has since been used by the authors over the last 8 years as a treatment in 117 patients with movement disorders (80 cases of Parkinson's disease, 20 cases of essential tremor, and 17 cases of various dyskinesias and dystonias including four multiple sclerosis).